Related Experiment Video
Updated: Feb 10, 2026

Comparing Bibliometric Analysis Using PubMed, Scopus, and Web of Science Databases
Published on: October 24, 2019
Differential musculoskeletal outcome reporting in patients receiving bempedoic acid or atorvastatin: a
Gianluca Gazzaniga1,2, Antonio Romio1, Chiara Galuppi1
1Department of Medical Biotechnology and Translational Medicine, Postgraduate School of Clinical Pharmacology and Toxicology, University of Milano, Milano, Italy.
Insights
Bempedoic acid (BA) shows higher odds of muscle-related adverse drug reactions (ADRs) than atorvastatin (ATO), but these are generally less severe. Increased attention is needed for muscle symptoms with BA, especially when combined with statins.
Area of Science:
- Cardiology
- Pharmacology
- Drug Safety
Background:
- Elevated low-density lipoprotein cholesterol (LDL-C) is a key risk factor for atherosclerotic cardiovascular disease.
- Statins are primary LDL-C-lowering drugs but can cause musculoskeletal disorders (MSDs), impacting patient adherence.
- Bempedoic acid (BA) is an alternative lipid-lowering agent with limited muscle activation, though recent data suggest potential muscle-related adverse drug reactions (ADRs).
Purpose of the Study:
- To compare muscle-related ADRs between bempedoic acid (BA) and atorvastatin (ATO).
- To evaluate the safety profile of BA concerning muscle-related adverse events in a real-world setting.
Main Methods:
- Analysis of ADR reports from the European spontaneous reporting system up to June 2024.
- Disproportionality analysis using Reporting Odds Ratios (RORs) to compare muscle-related ADRs between BA and ATO.
- Categorization of ADRs by patient demographics and event type.
Main Results:
- A total of 78,930 ADR reports were analyzed (2,667 for BA-only, 76,137 for ATO-only).
- Musculoskeletal disorders were significantly more frequent with BA than ATO (ROR 2.25).
- Muscle discomfort was more associated with BA, while severe events like rhabdomyolysis were more frequent with ATO; BA-related muscle ADRs were generally less severe.
Conclusions:
- Bempedoic acid (BA) recipients showed increased odds of muscle-related ADR reports compared to atorvastatin (ATO) recipients.
- Despite higher reporting odds, BA-associated muscle ADRs were characterized by more favorable clinical outcomes and lower severity.
- Clinicians should consider drug-induced muscle symptoms when prescribing BA, particularly in combination therapy with statins.
Background:
Elevated low-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease. Statins are the first choice LDL-C-lowering drugs, but often associated with musculoskeletal disorders (MSDs), limiting adherence. Bempedoic acid (BA) is a newer LDL-C-lowering prodrug acting upstream of statins with limited muscle tissue activation, offering an alternative to statin-intolerant patients. However, recent evidence suggests a higher-than-expected rate of muscle-related adverse drug reactions (ADRs). This study compares muscle-related ADRs for BA and atorvastatin (ATO) using the European spontaneous reporting system.
Methods:
ADRs reports were extracted from the earliest available date to 30 June 2024 and categorized by patient demographics and ADR type. Disproportionality analysis via Reporting Odds Ratios (RORs) was performed to assess differences in muscle-related ADRs between BA and ATO.
Results:
A total of 78,930 ADR reports, respectively 2,667 for BA-only, 76,137 for ATO-only and 126 for coadministration, were analysed. MSDs were the most frequently reported events, significantly higher in BA-only than ATO-only recipients (ROR 2.25, 95% CI 2.08-2.43). Musculoskeletal and muscle discomfort showed the highest odds of association with BA (6.97, 95% CI 4.46-10.91 and 6.37, 95% CI 4.58-8.85, respectively). Conversely, more severe conditions such as creatine phosphokinase increase (ROR 0.44, 95% CI 0.34-0.57) and rhabdomyolysis (ROR 0.05, 95% CI 0.02-0.10) were more frequently reported for ATO-only recipients. Overall, muscle-related ADRs reported for BA showed lower severity.
Conclusion:
Using a Registry-based approach, we found increased odds of muscle-related ADR reports in BA recipients compared to ATO, although characterized by more favourable clinical outcomes. It is suggested to pay increased attention to consider drug-related causes of muscle symptoms when BA is used, particularly when in combination with statins.
Related Concept Videos
Data Reporting and Recording
Receiver Operating Characteristic Plot
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:

